| Affiliation: | 1.INSERM Ethics Committee,Paris,France;2.National Centre for Biotechnology (CNB-CSIC), CSIC Ethics Committee and CIBERER-ISCIII,Madrid,Spain;3.Institute of Medical Radiology and Cell Research,University of Würzburg,Wūrzburg,Germany;4.University Panthéon-Assas,Paris,France;5.University of Geneva,Geneva,Switzerland;6.Catholic University of Louvain,Louvain,Belgium;7.National University of Ireland,Galway,Ireland;8.Research Group on Law, Science, Technology and Society (LSTS),Vrije Universiteit Brussel,Ixelles,Belgium;9.University of Malta,Msida,Malta;10.Faculty of Biology, Institute of Genetics and Biotechnology,University of Warsaw,Warsaw,Poland;11.University of Vienna,Vienna,Austria;12.UNESCO Chair on Bioethics,Medical University of Vienna,Vienna,Austria;13.German National Academy of Sciences Leopoldina,Halle,Germany;14.Instituto de Bioética, and Portuguese National Council for Ethics in Life Sciences,Universidade Católica Portuguesa,Porto,Portugal;15.European Research Ethics Committee Network (EUREC),Ixelles,Belgium;16.Head of Human Medicines Special Areas,European Medicines Agency,London,UK |
| Abstract: | In this consensus paper resulting from a meeting that involved representatives from more than 20 European partners, we recommend the foundation of an expert group (European Steering Committee) to assess the potential benefits and draw-backs of genome editing (off-targets, mosaicisms, etc.), and to design risk matrices and scenarios for a responsible use of this promising technology. In addition, this European steering committee will contribute in promoting an open debate on societal aspects prior to a translation into national and international legislation. |
